169 related articles for article (PubMed ID: 35731640)
1. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.
Chicharro P; Llamas-Velasco M; Armesto S; Herrera-Acosta E; Vidal D; Vilarrasa E; Rivera R; De la Cueva P; Martorell-Calatayud A; Ballescà F; Belinchón I; Carretero G; Rodríguez L; Romero-Maté A; Pujol-Montcusí J; Salgado L; Sahuquillo-Torralba A; Coto-Segura P; Baniandrés-Rodríguez O; Feltes R; Alsina M; Daudén E
Dermatol Ther; 2022 Aug; 35(8):e15653. PubMed ID: 35731640
[TBL] [Abstract][Full Text] [Related]
2. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
[TBL] [Abstract][Full Text] [Related]
3. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting.
Strober B; Patil D; McLean RR; Moore-Clingenpeel M; Guo N; Levi E; Lebwohl M
J Dermatolog Treat; 2022 Dec; 33(8):3178-3187. PubMed ID: 36026543
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.
Chicharro P; Llamas-Velasco M; Armesto S; Herrera Acosta E; Vidal D; Vilarrasa E; Rivera-Diaz R; De-la-Cueva P; Martorell-Calatayud A; Ballescà F; Belinchon I; Carretero G; Rodriguez L; Romero-Maté A; Pujol-Montcusí J; Salgado L; Sahuquillo-Torralba A; Coto-Segura P; Baniandrés Rodríguez O; Feltes R; Riera-Monroig J; Dauden E
Dermatol Ther; 2022 Dec; 35(12):e15929. PubMed ID: 36223184
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study.
Foley P; Spelman L; Murrell DF; Mate E; Tronnberg R; Lowe PM
Australas J Dermatol; 2022 Aug; 63(3):312-320. PubMed ID: 35816576
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
Augustin M; Dauden E; Mrowietz U; Konstantinou MP; Gerdes S; Kingo K; Szepietowski JC; Perrot JL; Cuccia A; Rissler M; Gathmann S; Sieder C; Orsenigo R; Jagiello P; Bachhuber T
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):431-440. PubMed ID: 32426889
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study.
Ding Y; Li W; Guan X; Liu N; Zhou Y; Li G; Wang X; Wang Z; Xiao X; Yang B; Lv C; Zhang C; Shi Y
Clin Transl Sci; 2023 Oct; 16(10):1803-1814. PubMed ID: 37644777
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
[No Abstract] [Full Text] [Related]
9. Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis.
Yu N; Peng C; Zhou J; Gu J; Xu J; Li X; Bi X; Deng H; Li X; Ding Y; Shi Y
Br J Dermatol; 2023 Sep; 189(4):437-446. PubMed ID: 37310289
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.
Dastoli S; Passante M; Loconsole F; Mortato E; Balato A; Piccolo V; Guarneri C; Macca L; Provenzano E; Valenti G; D'Amico D; Micali G; Musumeci ML; Palazzo G; Foti C; Romita P; Fabbrocini G; Megna M; Sammarra I; Bennardo L; Patruno C
J Dermatolog Treat; 2023 Dec; 34(1):2200868. PubMed ID: 37026590
[TBL] [Abstract][Full Text] [Related]
11. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
Megna M; Di Costanzo L; Argenziano G; Balato A; Colasanti P; Cusano F; Galluccio AG; Gambardella A; Lembo S; Mozzillo R; Scotto Di Luzio G; Fabbrocini G; Balato N
Expert Opin Biol Ther; 2019 Aug; 19(8):855-861. PubMed ID: 31140882
[No Abstract] [Full Text] [Related]
13. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
[TBL] [Abstract][Full Text] [Related]
14. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
Touw CR; Hakkaart-Van Roijen L; Verboom P; Paul C; Rutten FF; Finlay AY
Br J Dermatol; 2001 May; 144(5):967-72. PubMed ID: 11359382
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study.
Richard MA; Lacour JP; Konstantinou MP; Ruer-Mulard M; Joly P; Aractingi S; Auquier P; Pelvet B; Augustin ML; Mahé E; Chalmers RJG
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):677-684. PubMed ID: 32815591
[TBL] [Abstract][Full Text] [Related]
16. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
Elewski BE; Puig L; Mordin M; Gilloteau I; Sherif B; Fox T; Gnanasakthy A; Papavassilis C; Strober BE
J Dermatolog Treat; 2017 Sep; 28(6):492-499. PubMed ID: 28266243
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
Loft ND; Egeberg A; Rasmussen MK; Bryld LE; Gniadecki R; Dam TN; Iversen L; Skov L
Acta Derm Venereol; 2019 Dec; 99(13):1224-1230. PubMed ID: 31580465
[TBL] [Abstract][Full Text] [Related]
19. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.
Strober BE; Germino R; Guana A; Greenberg JD; Litman HJ; Guo N; Lebwohl M
J Dermatolog Treat; 2020 Jun; 31(4):333-341. PubMed ID: 31035822
[No Abstract] [Full Text] [Related]
20. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
Chaptini C; Quinn S; Marshman G
Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
